Analysts/Institutional Investor Meet/Con. Call Updates

Ref: NEPHROPLUS/SE/80 August 19, 2026 To To BSE Limited Na(cid:415)onal Stock Exchange of India Limited P.J. Towers, Dalal Street, 5th Floor, Exchange Plaza, Bandra (E), Mumbai – 400 001 Mumbai – 400 051 Scrip Code: 544647 Scrip Symbol: NEPHROPLUS Through: BSE Lis(cid:415)ng Centre Through: NEAPS Sub.: Transcript of Investors’ Conference Call on Q1FY27 Financial Results Ref.: Regulation 30, 46(2) and other applicable provisions of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015. Dear Sir/Madam, In continuation to our letter dated July 24, 2026 and August 12, 2026, please find attached Transcripts of the Investors’ Conference Call held on August 12, 2026 on the Un-audited Standalone and Consolidated Financial Results of the Company for the quarter ended June 30, 2026. The transcript of the said Conference Call has been uploaded on our website at www.nephroplus.com Kindly take the same on record. Yours faithfully, For Nephrocare Health Services Limited (Formerly Nephrocare Health Services Private Limited) Kishore Kathri Company Secretary and Head Legal Membership No.: F9895 Encl: a/a “Nephrocare Health Services Limited Q1 FY27 Earnings Conference Call” August 12, 2026 E&OE - This transcript is edited for factual errors. In case of discrepancy, the audio recordings uploaded on the stock exchange on August 12th, 2026 will prevail MANAGEMENT: MR. VIKRAM VUPPALA – CHAIRMAN AND MANAGING DIRECTOR MR. KAMAL SHAH – CO-FOUNDER MR. ROHIT SINGH – GROUP CHIEF EXECUTIVE OFFICER MR. PRASHANT GOENKA – GROUP CHIEF FINANCIAL OFFICER MODERATOR: MR. NAMAN – IIFL CAPITAL Page 1 of 23 Nephrocare Health Services Limited August 12, 2026 Moderator: Ladies and gentlemen, good day and welcome to Nephrocare Health Services Limited Q1 FY27 Earnings Conference Call hosted by IIFL Capital. This conference call may contain forward- looking statements about the company which are based on the beliefs, opinions, and expectations of the company as on date of this call. These statements are not the guarantees of future performance and involve risks and uncertainties that are difficult to predict. As a reminder, all participant lines will be in the listen-only mode, and there will be an opportunity for you to ask questions after the presentation concludes. Should you need assistance during the conference call, please signal an operator by pressing star then zero on your touchtone phone. Please note that this conference is being recorded. I now hand the conference over to Mr. Naman from IIFL Capital. Thank you, and over to you, Mr. Naman. Naman: Thank you. Good morning, everyone. On behalf of IIFL Capital Services Limited, I welcome you all to Q1 FY27 Earnings Conference Call of Nephrocare Health Services Limited. We are pleased to have with us the management team, represented by Mr. Vikram Vuppala, Chairman and Managing Director; Mr. Kamal Shah, Co-Founder; Mr. Rohit Singh, Group CEO; and Mr. Prashant Goenka, Group CFO of Nephro Health Services Limited. We will have opening remarks from the management followed by a question-and-answer session. Thank you, and over to you, Vikram. Vikram Vuppala: Thank you. Very good morning, everyone. This is Vikram Vuppala, Founder, Chairman and Managing Director. Thanks everyone for joining our first quarter of FY27 Earnings Conference Call. Along with me, I have Kamal, the Co-Founder, we have Group CEO Rohit Singh, and our Group CFO Prashant Goenka on this call. We began FY27 on a steady note, with Q1 revenues growing more than 20% year-on-year. This steady performance reflects the strength of the platform business we have built over the last 16 years, supported by disciplined execution, a resilient operating model, and the continued trust of our patients, payers, and hospital partners. The foundation of this platform was laid 16 years ago when we recognized that the growing prevalence of diabetes and hypertension would inevitably lead to a significant increase in chronic kidney disease. As kidney disease progresses, majority of these patients eventually move to stage five where you require dialysis or a transplant to survive. However, we also realized that delivering dialysis at scale would require addressing three fundamental pillars: quality of care, accessibility, and affordability. These principles continue to guide every decision we make at NephroPlus. Let me start our core pillar, quality. Dialysis is fundamentally different from most other healthcare services. It is not an elective procedure or a one-time procedure. It is a chronic life- sustaining treatment. Every dialysis session enables a patient to live another few days. In NephroPlus, we take quality as the cornerstone, and hence the quality team does not report into the business team. They report to the Chief Medical Officer directly. Page 2 of 23 Nephrocare Health Services Limited August 12, 2026 This enables our quality managers to do their clinical audit work without any pressures from the P&L owners. Every clinic undergoes a thorough clinical audit every month from one of the quality managers, and all of our clinics across the network are ranked on clinical outcomes every month. The second pillar is accessibility. While affordability and quality is supported through reimbursement and focus on clinical care, access to quality dialysis remains a much larger challenge. A patient typically requires dialysis three times every week and cannot be expected to travel long distances for every session. This is why we have consistently expanded beyond the metro cities in every country that we operate in, bringing organized dialysis care closer to where the patients live. Just this last quarter, we have launched NephroPlus in 17 new cities in India and 5 new cities in Philippines, which is a very important metric that Kamal and I track in terms of improving access to quality dialysis care. The third pillar is affordability. Dialysis is a lifelong treatment and for most patients, the financial burden can be onerous. Fortunately, dialysis is covered under various central and state government health schemes in India, and in most other healthcare systems globally, it is fully reimbursed by government in some form or manner. From the very beginning, we built our business around this reimbursement-led model, working closely with health insurance schemes, governments, and other payers to ensure that financial constraints do not become a barrier to access to life-sustaining treatment. Sincere focus on these three pillars, we have built one of the largest dialysis networks globally. With NephroPlus today operating 550 clinics across 357 cities in 5 countries, making us India's and also Asia's largest dialysis network by volume of treatments we do. Our international operations continue to complement our India business, allowing us to leverage the operating platform and capabilities we have built over several years. Also, I'd like to mention that India is still in the early days of the dialysis market life cycle. Majority of the patients who need dialysis still do not have access to dialysis, and also 80% of the dialysis capacity is still in the unorganized market wherein hospitals run their own dialysis operations. As hospitals evaluate their dialysis operations' financials closely, they will start outsourcing dialysis operations to pure-play dialysis networks like NephroPlus. Globally, hospitals do not run dialysis operations as you need two things to make decent margins in dialysis. You need massive scale and you need 100% focus. You need massive scale to generate margins in dialysis, and you need 100% focus to retain those margins. This shift from unorganized to organized dialysis market in India will play out over the next several years giving us good growth opportunity. At a macro level, we have consistently communicated our growth is driven by three growth levers. The first is increasing guest volumes across our existing clinics throug [Showing first 8,000 characters — download PDF for full document]